ScreenerHero

ELDN Eledon Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · eledon.com
2.420USD-1.22%Mkt Cap: 196.65M $P/E: —

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and preve…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap196.65M USD
Enterprise Value110.80M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-45.62M USD
Revenue/Share—
Last Price2.420 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees33
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.18
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B2.75
EPS (TTM)-0.88
EPS (Forward)-0.77
52W Range
1.35033% of range4.600
52W High4.600 USD
52W Low1.350 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-56.26%
ROA-26.99%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-62.34M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-22.94%
Net Debt-88.29M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.01
Current Ratio7.90
Quick Ratio7.57
Book Value/Sh0.89 USD
Cash/Share1.09 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateOct 5, 2020
Splits
Last Split1:18
Split DateOct 5, 2020
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)9.000 USD
Upside (mean)+271.9%
Target Range7.000 USD – 12.00 USD
7.000+271.9% to mean12.00
# Analysts5
Ownership
Shares Out.81.26M
Float74.60M
Insiders0.33%
Institutions58.64%
Short Interest
Short Ratio8.7d
Short % Float10.17%
Short % Out.10.16%
Shares Short8.26M
Short (prev mo.)6.29M
Technical
SMA 503.118 (-22.4%)
SMA 2003.037 (-20.3%)
Beta0.85
S&P 52W Chg16.45%
Avg Vol (30d)902.82K
Avg Vol (10d)950.21K
Technical Indicators
RSI (14)29.5
MACD-0.2058
MACD Signal-0.2108
MACD Hist.+0.0050
BB Upper2.958 USD
BB Middle2.650 USD
BB Lower2.343 USD
BB Width23.21%
ATR (14)0.1512 USD
Vol Ratio (20d)0.63x